Antibody Detection of HP1α Phosphorylation for Aurora B Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anticancer agents targeting chromosome instability in cancer cells are ineffective due to a lack of understanding of the molecular mechanism, and existing drugs often have low specificity and high toxicity to normal cells.
Innovation Solution
A method for screening anticancer agents that evaluates Aurora B activity through the phosphorylation of HP1α and HP1γ, using an antibody to detect specific phosphorylation sites, thereby identifying compounds that target improper cell division in cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Aurora kinase inhibitors are used to target chromosome instability in cancer cells, then cancer cell proliferation is suppressed, but the inhibitors lack specificity and cause high toxicity to normal cells
Solution Approach 1:
The patent applies local quality by detecting phosphorylation at specific local sites (Ser92 of HP1α and Ser83 of HP1γ) to evaluate Aurora B activity. This localized detection approach enables differentiation between cancer cells with abnormal Aurora B activity and normal cells, allowing selective targeting while sparing normal tissues from inhibitor toxicity
Solution Approach 2:
The patent utilizes parameter changes by measuring phosphorylation levels of HP1 proteins as a biomarker to identify cancer cells with dysregulated Aurora B activity. This parameter-based selection enables personalized medicine approaches where patients are selected based on their tumor's phosphorylation profile, ensuring the inhibitor is administered only when Aurora B dysregulation is present, thereby reducing unnecessary toxicity to normal cells
2Productivity
If existing Aurora kinase inhibitors are used, then cell division is inhibited, but the inhibitors bind to ATP binding sites of other kinases causing off-target effects
Solution Approach 1:
The patent introduces phosphorylation detection of HP1 proteins as an intermediary biomarker that specifically reflects Aurora B activity. This intermediary measurement system allows for selective identification of cancer cells with abnormal Aurora B function before administering inhibitors, ensuring that only cells with the target abnormality are affected while avoiding off-target binding to other kinases
Solution Approach 2:
The patent implements feedback by using phosphorylation status of HP1 proteins as a readout to evaluate Aurora B activity levels. This feedback mechanism enables researchers to identify compounds that specifically modulate Aurora B function in cancer cells with chromosome instability, allowing for the selection of highly specific inhibitors that do not cross-react with other kinases
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the development of molecularly targeted drugs that selectively target cancer cells with chromosome instability, potentially treating a wide variety of cancers, including drug-resistant types, with reduced side effects on normal cells.
Implementation Method 1
determining Aurora B activity based on phosphorylation of HP1α and/or HP1γ as an indicator
Implementation Method 2
an antibody for specifically recognizing phosphorylation of serine at position 92 of HP1α
Data Source
AI summary
The inventors have found that the interaction between HP1 and INCENP can serve as an indicator for chromosome instability and established a method for evaluating chromosome instability of cancer cells. The evaluation system can be used for screening of anticancer agent with a new-concept of targeting chromosome instability of cancer cells. The inventors further prepared an antibody for specifically recognizing phosphorylation of serine at position 92 of HP1α, by which the action of Aurora B can be evaluated. The interaction between HP1 and INCENP can be readily evaluated by the antibody.